[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-365023-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-365023-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","diverse-potential-of-chimeric-antigen-receptor-engineered-cell-therapy-beyond-cancer","Diverse potential of chimeric antigen receptor-engineered cell therapy - Beyond cancer","","CAR-engineered cell therapies have achieved major progress in hematological cancer, driving growing interest in their application to non-cancerous conditions. This review synthesizes recent research with emphasis on CAR-T therapy for infectious diseases, autoimmune diseases, cardiac disorders, and immune-mediated transplant complications, while also outlining current barriers to wider clinical adoption. Ongoing research and iterative technological improvements support its future promise as a versatile therapeutic tool.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/diverse-potential-of-chimeric-antigen-receptor-engineered-cell-therapy-beyond-cancer/365023/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/diverse-potential-of-chimeric-antigen-receptor-engineered-cell-therapy-beyond-cancer/365023.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus of this review on CAR-engineered cell therapy?","Question",{"text":63,"@type":64},"The review summarizes latest CAR-engineered cell therapy research, focusing especially on CAR-T therapy for non-cancerous diseases and the obstacles for broader clinical use.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which non-cancer disease areas does the review highlight?",{"text":68,"@type":64},"It highlights infectious diseases, autoimmune diseases, cardiac diseases, and immune-mediated disorders related to transplantation.",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges are emphasized for using CAR cell therapy beyond cancer?",{"text":72,"@type":64},"Safety, efficacy, and practical implementation remain challenging, requiring further technological optimization and clinical translation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},365023,1790241472,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","DOI: 10.1002/ctm2.70306  \nREVIEW  \nDiverse potential ofchimeric antigen receptor-engineered cell therapy: Beyond cancer  \nLvying Wu1  Lingfeng Zhu2  Jin Chen1,2   \n1 Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China  \n2Minimally Invasive Urology and Translational Medicine Center, Fuzhou First General Hospital Affiliated With Fujian Medical University, Fuzhou, Fujian, China  \nCorrespondence  \nJin Chen, Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University, 368 Yehai Avenue, Haikou, 570311, Hainan, China. [Email:](Email: kingchen81@hainmc.edu.cn)[ kingchen81@hainmc.edu.cn](Email: kingchen81@hainmc.edu.cn)  \nGraphical Abstract  \n1. In theory, CAR-engineering therapy can achieve therapeutic effects by targeting cells expressing specific antigens and thereby eliminating or regulating disease-related cell subpopulations.  \n2. Although CAR-engineering therapy is currently only approved for the treatment of cancer, it has also shown potential in non-tumour diseases.  \n3. Immune cells from different sources expand the potential applications of CARengineering therapy.  \nDOI: 10.1002/ctm2.70306  \nREVIEW  \nDiverse potential ofchimeric antigen receptor-engineered cell therapy: Beyond cancer  \nLvying Wu1  Lingfeng Zhu2  Jin Chen1,2   \n1 Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China  \n2Minimally Invasive Urology and Translational Medicine Center, Fuzhou First General Hospital Affiliated With Fujian Medical University, Fuzhou, Fujian, China  \nCorrespondence  \nJin Chen, Institute of Clinical Medicine, The Second Affiliated Hospital of Hainan Medical University, 368 Yehai Avenue, Haikou, 570311, Hainan, China. [Email:](Email: kingchen81@hainmc.edu.cn)[ kingchen81@hainmc.edu.cn](Email: kingchen81@hainmc.edu.cn)  \nFunding information  \nKey Research and Development Projects of Hainan Province of China,  \nGrant/Award Number: ZDYF2022SHFZ133; Science and Technology program of Fujian Provincial Health Commission, Grant/Award Number: 2024CXA051  \nAbstract  \nBackground: Chimeric antigen receptor (CAR)-engineered cell therapies have made significant progress in haematological cancer treatment. This success has motivated researchers to investigate its potential applications in non-cancerous diseases, with substantial strides already made in this field.  \nMain Body: This review summarises the latest research on CAR-engineered cell therapies, with a particular focus on CAR-T cell therapy for non-cancerous diseases, including but not limited to infectious diseases, autoimmune diseases, cardiac diseases and immune-mediated disorders in transplantation. Additionally, the review discusses the current obstacles that need to be addressed for broader clinical applications.  \nConclusion: With ongoing research and continuous improvements, CARengineered cell therapy holds promise as a potent tool for treating various diseases in the future.  \nKEYWORDS  \nautoimmune diseases, cardiac diseases, chimeric antigen receptor, infectious diseases, transplantation  \nKey points  \n∙ CAR-engineered cell therapy has expanded beyond cancer to treat autoimmune diseases, infections, cardiac diseases, and transplant-related rejection.  \n∙ The CAR platform is diverse, with various cell types such as CAR-T, CAR-NK, and CAR-M potentially suited for different disease contexts.  \n∙ The safety, efficacy, and practicality of CAR cell therapy in non-cancer diseases remain challenging, requiring further technological optimization and clinical translation.  \n1  BACKGROUND that grant immune effector cells the ability to recognise specific antigens. Since the concept of CAR was  \nChimeric antigen receptors (CARs) are receptor molecules manufactured through genetic engineering techniques  \nfirst proposed in 1987,1 CAR structures have undergone multiple generations of development,2–8 with design  \nThis is an open access article ","cbCaig7OJs6CcZMu","https://ap.wps.com/l/cbCaig7OJs6CcZMu","pdf",7786749,33,"English","# Graphical Abstract\n## Therapeutic targeting and disease relevance\n## Approved scope and non-tumor potential\n## Source diversity and expanded applications\n# Abstract\n## Background\n## Main Body\n## Conclusion\n# Key points\n# 1 BACKGROUND","[{\"question\":\"What is the main focus of this review on CAR-engineered cell therapy?\",\"answer\":\"The review summarizes latest CAR-engineered cell therapy research, focusing especially on CAR-T therapy for non-cancerous diseases and the obstacles for broader clinical use.\"},{\"question\":\"Which non-cancer disease areas does the review highlight?\",\"answer\":\"It highlights infectious diseases, autoimmune diseases, cardiac diseases, and immune-mediated disorders related to transplantation.\"},{\"question\":\"What challenges are emphasized for using CAR cell therapy beyond cancer?\",\"answer\":\"Safety, efficacy, and practical implementation remain challenging, requiring further technological optimization and clinical translation.\"}]","Diverse potential of chimeric antigen receptor-engineered cell therapy - Beyond cancer | PDF",1790159754,83,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/019d972f17258e1bb9cf39c65b699468.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/476f01d796008b66f24f76aeb6004d2a.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91a3acaa3cf0f244879a2f916c90a11f.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e409318a605969ee7abbca70333822c.webp",980,1287]